Background: Anti-PD-1 monotherapy has proven effective for the patients (pts) with MGC. However, the identification of biomarkers for predicting clinical outcomes remain as critical needs. We aimed to identify baseline characteristics associated with time to treatment failure (TTF) or overall survival (OS) for anti-PD-1/PD-L1 monotherapy as second-or later-line in MGC. Methods: Routine blood count parameters and clinical characteristics at baseline were retrospectively investigated in 31 pts with MGC in Aichi Cancer Center Hospital. Endpoints were TTF and OS following anti-PD-1/PD-L1 monotherapy. KaplanMeiyer and Cox regression analysis were applied for survival analyses.
Background: Recently, anti-PD-1/PD-L1 antibodies have shown promising activities in metastatic gastric cancer (MGC). However, little is known about detailed clinicopathological features of PD-L1 expression in patients (pts) with MGC. Methods: Pts with histologically confirmed MGC were eligible for this prospective observational study. PD-L1 expression on tumor cell (TC) or inflammatory cell (IC) and mismatch repair (MMR) were analyzed by immunohistochemistry (IHC). Epstein-Barr virus (EBV) was detected by in situ hybridization. The expressions of tyrosine kinase receptors (RTKs) such as HER2, EGFR and MET and cancer genome alterations were also evaluated by IHC or next generation sequencing. Result: A total of 237 pts were enrolled from September 2015 to December 2016. PD-L1 expression on TC and IC was positive in 27 (11.4%) and 167 pts (70.5%), respectively. One hundred and seventy-one pts (72.2%) had positive PD-L1 expression on either TC or IC. MMR deficient (D-MMR) and EBV was detected in 14 (6.9%, n ¼ 202) and 14 pts (5.9%, n ¼ 237), respectively. PD-L1 expression on TC was more frequently observed in pts with D-MMR (P < 0.001) and KRAS mutation (P < 0.001), while that on IC was more frequently observed in pts with EBV þ (P ¼ 0.045), lymph node metastasis (P ¼ 0.001), and lung metastasis (P ¼ 0.045). In contrast, pts with peritoneal metastasis were associated with less frequent PD-L1 expression in IC (P ¼ 0.003). A significant association was not observed between PD-L1 expression and RTKs expression or presence of other gene alterations. D-MMR was significantly associated with intestinal type (P ¼ 0.026) and absence of liver metastasis (P ¼ 0.022). PD-L1 expression on either TC or IC was not prognostic factor (HR; 0.92, P ¼ 0.741). Seven pts with D-MMR and seven pts with EBVþ MGC were enrolled in clinical trials of anti-PD-1/PD-L1 antibody. Conclusion: PD-L1 expression in MGC was associated with some clinicopathological features.
O3 À 9 À 3 Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab Background: Some phase II and III studies of second-line chemotherapy for metastatic or advanced gastric cancer have been reported in recent years. Irinotecan is one of the standard regimen for second-line chemotherapy. The efficacy of continuing trastuzumab(Tmab) beyond progression in patients(pts) who had previously been treated with Tmab plus standard first line chemotherapy has not been reported. We conducted this study to assess the efficacy and safety of Tmab with irinotecan in HER2-positive gastric cancer pts previously treated with Tmab (UMIN ID: 000007636). Methods: Patients with HER2-positive gastric cancer who were previously treated with Tmab and failed were included. Patients received Tmab every 3 weeks and irinotecan every 2 weeks. Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), six-month survival rate, safety, and so on. Results: Only 16 patients were enrolled from 9 institutions in three years during a preplanned registration period. We stopped this study on the way, unfortunately. One patient was excluded and 15 were analyzed. Median age was 65, male/female; 9/6, ECOG PS 0/1; 8/7, and IHC 3þ group/IHC 2þ and FISH positive; 10/5, respectively. RR was 7% and disease control rate was 53%. Median PFS and overall survival (OS) were 2.4 (95%C.I.; 0.0-5.2 months) and 9.7 months (95%C.I.; 8.2-11.2 months), respectively. Six-month PFS rate was 13%. In sub-group analysis by HER2 status, median PFS of IHC 3þ and IHC 2þ/FISH positive were 2.2 and 2.4 months, respectively. Median OS of each groups were 8.8 and 10.8 months. The most frequently grade 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). Conclusions: The study was closed prematurely due to poor accrual. It seemed that continued use of Tmab and irinotecan beyond disease progression has not clinical benefit in HER2-positive metastatic or advanced gastric cancer patients previously treated with Tmab. Eli Lilly Japan K.K Background: In this study (NCT02359058), safety, tolerability, pharmacokinetics (PK) and efficacy of ramucirumab (RAM) on D1 and D8 every 3 weeks (q3w) in combination with 3 platinum/fluoropyrimidine doublet regimens were evaluated in Japanese pts with chemo naive mGC. Methods: This was a multicenter, single arm, phase 1b study. On each cycle, pts received 8 mg/kg RAM at D1 and D8, q3w, in combination with XP q3w: capecitabine (2000 mg/m2, D1-D14)þcisplatin (80 mg/m2, D1); SP every 5 weeks (q5w): S-1 (40 mg/m2 bid, D1-D21)þcisplatin (60 mg/m2, D8); or SOX q3w: S-1 (40 mg/m2 bid, D1-D14)þoxaliplatin (100 mg/m2, D1). The primary objective was to confirm safety and tolerability of the new combination; and the secondary objectives were to evaluate PK and efficacy. Results: Six pts were treated in each cohort. Compared with the approved dose (8 mg/ kg every 2-weeks, q2w), this new RAM dose produced higher mean trough concentrations of RAM in all cohorts. The mean trough concentrations of RAM were consistent across all cohorts, and exceeded biologically relevant target levels throughout treatment. The new RAM dosing in combination with all regimens was generally well tolerated in all cohorts. Two pts in SP and 1 in SOX had treatment-related SAE. These included 1 pt with decreased appetite and 1 pt with pelvic venous thrombosis in SP and 1 pt with enterocolitis in SOX, which was considered a dose limiting toxicity. There were no treatment-related deaths. Notably, neutropenia (5 in XP, 5 in SP and 4 in SOX), decreased appetite (3 in XP, 6 in SP and 3 in SOX), and hypertension (3 in XP, 4 in SP and 2 SOX) of any grade were observed. Disease control rate was 100% and overall response rate was 45% in 11 patients with measurable lesions. Median progression-free survival was 7.6 months (95% CI, 2.5-11.8 months). Conclusion: RAM at 8 mg/kg D1 and D8 q3w in combination with XP, SP or SOX was well-tolerated and demonstrated anti-tumor activity in chemo naive Japanese mGC pts.
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